JP2006030037A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006030037A5 JP2006030037A5 JP2004210868A JP2004210868A JP2006030037A5 JP 2006030037 A5 JP2006030037 A5 JP 2006030037A5 JP 2004210868 A JP2004210868 A JP 2004210868A JP 2004210868 A JP2004210868 A JP 2004210868A JP 2006030037 A5 JP2006030037 A5 JP 2006030037A5
- Authority
- JP
- Japan
- Prior art keywords
- nuclear receptor
- compound
- candidate compound
- modulates
- covalently bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 22
- 102000006255 nuclear receptors Human genes 0.000 claims 22
- 108020004017 nuclear receptors Proteins 0.000 claims 22
- 238000000034 method Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000000547 structure data Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004210868A JP4525221B2 (ja) | 2004-07-16 | 2004-07-16 | 受容体リガンド同定法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004210868A JP4525221B2 (ja) | 2004-07-16 | 2004-07-16 | 受容体リガンド同定法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006030037A JP2006030037A (ja) | 2006-02-02 |
| JP2006030037A5 true JP2006030037A5 (enExample) | 2007-08-23 |
| JP4525221B2 JP4525221B2 (ja) | 2010-08-18 |
Family
ID=35896572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004210868A Expired - Fee Related JP4525221B2 (ja) | 2004-07-16 | 2004-07-16 | 受容体リガンド同定法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4525221B2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2181710A1 (en) * | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Ligands for modulation of orphan receptor-gamma (NR1F3) activity |
| JP2011037739A (ja) * | 2009-08-10 | 2011-02-24 | Pola Chemical Industries Inc | 組成物 |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| JP2023047726A (ja) * | 2021-09-27 | 2023-04-06 | 富士通株式会社 | 初期構造生成装置、初期構造生成方法及び初期構造生成プログラム |
| WO2024204454A1 (ja) * | 2023-03-29 | 2024-10-03 | 国立研究開発法人理化学研究所 | 融合タンパク質 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002102364A1 (ja) * | 2001-06-18 | 2004-09-30 | 山田 幸子 | ＰＰＡＲγ作動性医薬組成物 |
| KR101021817B1 (ko) * | 2001-07-17 | 2011-03-17 | 데이진 가부시키가이샤 | ＰＰＡＲ δ활성화 작용을 측정하는 것을 특징으로 하는 물질의 선택방법 및 약제 |
| GB0119920D0 (en) * | 2001-08-15 | 2001-10-10 | Pfizer Ltd | New use |
-
2004
- 2004-07-16 JP JP2004210868A patent/JP4525221B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sparks et al. | Use of surface plasmon resonance (SPR) to determine binding affinities and kinetic parameters between components important in fusion machinery | |
| Echavarren | Gold catalysis: Carbene or cation? | |
| W. Pike | Considerations in the development of reversibly binding PET radioligands for brain imaging | |
| Goldstein et al. | Recommendations for improved standardization of immunohistochemistry | |
| Hermeke et al. | Direct Catalytic Access to N‐Silylated Enamines from Enolizable Imines and Hydrosilanes by Base‐Free Dehydrogenative Si N Coupling | |
| Simon et al. | Finding the optimal surface density of aptamer monolayers by SPR imaging detection‐based aptamer microarrays | |
| Chen et al. | Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics | |
| JP2014074724A5 (enExample) | ||
| JP2012526554A5 (enExample) | ||
| JP2015536446A5 (enExample) | ||
| JP2009521215A5 (enExample) | ||
| JP2002506973A5 (enExample) | ||
| JP2008530582A5 (enExample) | ||
| JP2006517093A5 (enExample) | ||
| Sindelar et al. | Library Screening by Means of Mass Spectrometry (MS) Binding Assays—Exemplarily Demonstrated for a Pseudostatic Library Addressing γ‐Aminobutyric Acid (GABA) Transporter 1 (GAT1) | |
| Lee et al. | Separation of methylated histone peptides via host-assisted capillary electrophoresis | |
| JP2015502547A5 (enExample) | ||
| Tröster et al. | NVP‐BHG712: Effects of regioisomers on the affinity and selectivity toward the EPHrin family | |
| JP2006030037A5 (enExample) | ||
| JP2012509062A5 (enExample) | ||
| JP2005106609A5 (enExample) | ||
| RU2014138543A (ru) | Репрограммирование эффекторных белковых взаимодействий для исправления эпигенетических дефектов в злокачественной опухоли | |
| JP2008534927A5 (enExample) | ||
| Schräml et al. | Kinetic screening in the antibody development process | |
| JP2019526792A5 (enExample) |